ABBVIE
A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 159
- Registration Number
- NCT05316233
- Locations
- 🇺🇸
Steve Yoelin MD Medical Associate Inc /ID# 239072, Newport Beach, California, United States
🇺🇸Cosmetic Laser Dermatology /ID# 239121, San Diego, California, United States
🇺🇸Research Institute of the Southeast, LLC /ID# 239070, West Palm Beach, Florida, United States
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 34
- Registration Number
- NCT05308654
- Locations
- 🇺🇸
Tulane University School of Medicine /ID# 244854, New Orleans, Louisiana, United States
🇺🇸American Oncology Partners of Maryland /ID# 244858, Bethesda, Maryland, United States
🇺🇸Atrium Health Levine Cancer Institute /ID# 243420, Charlotte, North Carolina, United States
A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 17
- Registration Number
- NCT05305222
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc /ID# 164197, Cypress, California, United States
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT05296447
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸University Retina and Macula Associates, PC, Oak Forest, Illinois, United States
🇺🇸Retina Consultants San Diego, Poway, California, United States
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 106
- Registration Number
- NCT05291234
- Locations
- 🇺🇸
Tucson Neuroscience Research /ID# 244957, Tucson, Arizona, United States
🇺🇸Irvine Clinical Research /ID# 239469, Irvine, California, United States
🇺🇸Alzheimer's Research and Treatment Center - Stuart /ID# 245477, Stuart, Florida, United States
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT05286229
- Locations
- 🇯🇵
Kanazawa University Hospital /ID# 240948, Kanazawa-shi, Ishikawa, Japan
🇯🇵Okayama Medical Center /ID# 240949, Okayama-shi, Okayama, Japan
🇯🇵National Cancer Center Hospital East /ID# 240943, Kashiwa-shi, Chiba, Japan
A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 226
- Registration Number
- NCT05283681
- Locations
- 🇺🇸
Acpru /Id# 210844, Grayslake, Illinois, United States
🇺🇸PPD Clinical Research Unit - Austin /ID# 211456, Austin, Texas, United States
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT05283694
- Locations
- 🇺🇸
Acpru /Id# 165737, Grayslake, Illinois, United States
Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05274087
- Locations
- 🇺🇸
Acpru /Id# 223662, Grayslake, Illinois, United States
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 394
- Registration Number
- NCT05274100
- Locations
- 🇺🇸
PPD Clinical Research Unit - Austin /ID# 222361, Austin, Texas, United States
🇺🇸Altasciences Clinical Los Angeles, Inc /ID# 222238, Cypress, California, United States
🇺🇸Anaheim Clinical Trials LLC /ID# 222821, Anaheim, California, United States